CTLA4 and prostate cancer: Conversely, ongoing efforts are evaluating the efficacy of combining CTLA-4 and TGF-β inhibitors against castrate-resistant prostate cancer in mice, citing decreased bone metastasis growth and T regs, while increasing Th1; findings the researchers expect to advance into clinical application.